Industrial enzyme engineering sits at the intersection of protein engineering, process chemistry, and large-scale manufacturing. The customers are specialty chemical producers, pharmaceutical intermediates manufacturers, agrochemical companies, food and detergent ingredient makers. The objectives are concrete and quantitative — turnover number at the operating temperature, substrate scope at the relevant concentration, half-life in the process solvent, regiospecificity that meets product purity targets.
This article is a playbook for what an industrial enzyme engineering project actually looks like when delivered by a CRO. The methods are mature; the integration is the value.
The industrial enzyme value chain
Industrial biocatalysis is now embedded across multiple sectors:
- Pharmaceutical intermediates: transaminases for chiral amine synthesis, ketoreductases for alcohol synthesis, lipases for kinetic resolution, monooxygenases for selective hydroxylation.
- Specialty chemicals: nitrilases, esterases, lyases for chiral building blocks. Polymerases and glycosyltransferases for bioplastics monomers.
- Agrochemicals: enzymes for crop protection compound synthesis. Glufosinate, phosphinothricin, and adjacent chiral chemistries.
- Food and feed: phytases, proteases, amylases, lipases for animal nutrition and food processing.
- Detergents: high-temperature stable proteases and lipases for cleaning formulations.
- Biofuels and bioplastics: cellulases, lipases, polyhydroxyalkanoate synthases.
Each sector has different performance bars and regulatory contexts, but the engineering work follows the same playbook.
Common targets — what gets engineered
The repeat targets across industries:
Transaminases for chiral amine synthesis. Engineering objectives: substrate scope (accepting bulky α-keto acids), stability at the process pH, activity in organic cosolvents (DMSO, isopropanol).
Lipases for kinetic resolution. Engineering objectives: enantioselectivity (E > 100), regiospecificity for sn-1 vs sn-3 positions in triglycerides, activity in non-aqueous solvents.
Ketoreductases for alcohol synthesis. Engineering objectives: substrate scope, cofactor preference (NADH vs NADPH), thermostability at operating temperature.
Oxidoreductases and monooxygenases for selective oxidation. Engineering objectives: substrate scope, peroxide tolerance, regiospecificity, total turnover number before inactivation.
Hydrolases and esterases for ester synthesis and hydrolysis. Engineering objectives: substrate scope, pH stability, product inhibition tolerance.
Glycosyltransferases for complex sugar synthesis. Engineering objectives: donor and acceptor substrate scope, regiospecificity, expression yield.
For each enzyme class, a mature literature exists on which positions tolerate mutation and which engineering approaches deliver. The CRO advantage is integrating that literature with high-throughput experimental work.
Engineering objectives
The dimensions an industrial enzyme campaign optimizes:
Substrate scope. The wild-type enzyme catalyzes a natural substrate. The industrial application needs a structurally different (often bulkier, sometimes charged) substrate. Engineering targets are usually the active-site loops that gate substrate access.
Solvent tolerance. Industrial processes often run in cosolvent (DMSO, methanol, isopropanol) or partial-aqueous systems to solubilize substrates. Wild-type enzymes denature in cosolvent; engineered variants tolerate 30–60% organic without significant activity loss.
Regiospecificity and stereoselectivity. The enzyme must produce the desired isomer at >99% selectivity for product purity. Engineering targets are typically the residues that orient the substrate in the active site.
Thermostability. Covered in detail in enzyme thermostability engineering. Tm shifts of +10 to +20 °C are routine; higher gains require sustained iteration.
Product inhibition tolerance. Many enzymes are inhibited by their own product, capping conversion at low concentrations. Engineering targets are the product-binding subsite, expanded or destabilized to lower product affinity.
Half-life in the process. The integrated measure that customers care about. Combines thermostability, solvent tolerance, oxidation resistance, and aggregation propensity into one number: how long the enzyme stays active in the actual process.
Workflow — DMS, focused mutagenesis, AI design, scale-up
The CRO workflow chains four phases:
Phase 1 — Discovery and characterization (4–8 weeks). Express the wild-type. Validate activity on the customer’s substrate. Establish baseline performance metrics. Map the structural and sequence landscape — homologs, structural model, predicted hot spots.
Phase 2 — Library design and screening (8–16 weeks). Build the focused library (DMS-scale or directed-evolution-scale, depending on screening capacity). Screen against the relevant performance dimensions. Generate the position-by-position fitness map. Identify the top single-mutant hits. We covered DMS methodology in DMS fitness landscapes and AI integration in AI and DMS for enzyme engineering.
Phase 3 — Combinatorial optimization (8–12 weeks). Combine top single mutants. Test for positive epistasis. Iterate as needed. Output: a sequence-defined evolved variant meeting the performance specification.
Phase 4 — Scale-up and delivery (4–8 weeks). Express the evolved variant in the customer’s preferred production host (typically E. coli or Pichia pastoris for industrial enzymes, sometimes Bacillus for proteases and amylases). Characterize at scale. Deliver the construct plus the engineering history documentation.
Total timeline: 6–11 months. Total cost is dominated by Phase 2 screening; Phases 1, 3, and 4 are predictable.
The integrated approach
The CRO advantage is in the integration. Most academic and in-house programs can run one of the methods well — directed evolution, or DMS, or computational design. A CRO running industrial campaigns combines all of them in the right sequence:
- Consensus design + Rosetta ddG as the first-pass focused library, before any high-throughput experiments.
- DMS to map the tolerable mutations exhaustively, in one library.
- Directed evolution to iterate on the DMS-revealed top hits and find epistatic combinations the single-mutant scan misses.
- AI tools (ProteinMPNN-driven sequence sampling, ESM-derived fitness predictions) to focus combinatorial libraries.
- Computational scaffold design when none of the natural homologs is a good starting point — rare in industrial work but increasingly relevant for new chemistries.
The methods compound. A 16-month all-classical-directed-evolution campaign can be compressed to 9 months by starting with a consensus + DMS pass. The reverse is also true: AI-only approaches without wet-lab iteration rarely deliver industrial-grade variants.
We covered the rational design vs evolution comparison in rational enzyme engineering and the directed evolution side in the directed evolution technical guide.
When to use a CRO vs build in-house
The economic case for a CRO:
- One-time program: building enzyme engineering infrastructure for a single product doesn’t amortize. Use a CRO.
- Multiple programs but small team: CROs handle the labor-intensive screening and engineering work; the customer keeps the strategic decisions and IP.
- Specialized capability requirement: DMS infrastructure, high-throughput automation, AI-design pipelines are expensive to build and maintain. CROs amortize them.
- Speed: dedicated CRO teams hit a 6–12 month timeline that in-house teams typically can’t match without dedicated headcount.
The case against:
- Strategic IP: if the enzyme is the company’s core IP and engineering trajectory must stay internal, in-house is the right answer.
- Continuous iteration: programs that need ongoing engineering across many years often justify in-house investment.
For most industrial enzyme programs — especially in mid-cap chemical and pharma companies — the CRO route delivers faster and cheaper than building.
Decision summary
For a new industrial enzyme engineering program:
- Define the performance specification precisely (numbers, conditions, units).
- Characterize the wild-type. Confirm what already works and what doesn’t.
- Choose the engineering method based on screening infrastructure: DMS-led if high-throughput is available, directed evolution-led if not, AI-augmented in both cases.
- Run the campaign in three phases (discovery → library → combinatorial), with checkpoint reviews at each phase boundary.
- Plan scale-up early. The construct that wins the engineering campaign is not always the one that expresses well at scale; co-validate yield during the engineering work.
If you’re scoping an industrial enzyme engineering program, see our enzyme engineering services or reach out via the contact page. For multi-target or multi-objective programs, see protein engineering services.
Related Ranomics services
- Enzyme engineering: Industrial biocatalysis enzyme engineering campaigns.
- Directed evolution: The iterative method underlying most industrial enzyme campaigns.
- Protein engineering: Full protein engineering portfolio including non-enzyme targets.